-

06:45:35 PM

LIVE Real Time GH Stock Market News

GH - Guardant Health Inc

04/12/21 4:05 PM

Nasdaq : GH

Guardant Health to Report First Quarter Financial Results on May 6, 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 6, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific

RHEA-AI

neutral

04/10/21 8:35 AM

Nasdaq : GH

Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers

Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company's proprietary blood tests to advance precision oncology.Key findings

RHEA-AI

neutral

04/01/21 8:05 AM

Nasdaq : GH

Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer

Guardant Health, Inc. (Nasdaq: GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant Reveal(TM) liquid biopsy test for the detection and monitoring of minimal residual disease (MRD) in patients with early-stage cancer (stage

RHEA-AI

positive

03/30/21 8:05 AM

Nasdaq : GH

Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360(R) CDx Test

Guardant Health, Inc. (Nasdaq: GH) announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Guardant360 (R) CDx test. The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehensive tumor mutation

RHEA-AI

very positive

03/26/21 8:05 AM

Nasdaq : GH

Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer

For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is often recommended for first-line treatment. A new study in JCO Precision Oncology shows the Guardant360 (R) liquid biopsy test provides an early indication of treatment response to

RHEA-AI

very positive

03/24/21 8:05 AM

Nasdaq : GH

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly

RHEA-AI

neutral

03/02/21 8:05 AM

Nasdaq : GH

Guardant360(R) CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360 (R) CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify non-small cell lung

RHEA-AI

very positive

02/24/21 4:05 PM

Nasdaq : GH

Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.Recent

RHEA-AI

neutral

02/17/21 4:03 PM

Nasdaq : GH

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences.10 th Annual SVB Leerink Global Healthcare ConferenceFireside Chat on Friday, February 26 th at 1:20 p.m. Pacific Time / 4:20

RHEA-AI

neutral

02/04/21 4:03 PM

Nasdaq : GH

Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021. Company management will be webcasting a corresponding conference call beginning at

RHEA-AI

neutral